Li Yang, Li Lei, Wu Junyi, Qin Jun, Dai Xueming, Jin Tao, Xu Junming
Department of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Shanghai 200080, China.
Am J Cancer Res. 2021 Feb 1;11(2):416-440. eCollection 2021.
YEATS domain-containing protein 4 (YEATS4) is implicated in several oncogenic signaling pathways, and its expression is involved in various types of cancer; regardless, the pathophysiologic effects of YEATS4 on breast cancer remain unclear. This study finds that YEATS4 is increasingly expressed with breast cancer progression, and its expression is related to poor outcome and distant metastasis. YEATS4 overexpression in breast cancer cells strengthens their malignant characteristics and , particularly inducing epithelial-to-mesenchymal transition (EMT) and consequently, metastatic capability in breast cancer cells. By contrast, deleting YEATS4 in breast cancer cells with high-grade malignancy reduced these characteristics. With regard to the molecular mechanism, YEATS4 mediates histone H3K27ac at specific sites of the ZEB1 promoter to regulate its expression at the transcription level. Depleting ZEB1 blocks YEATS4-induced EMT, migration, invasion, and metastasis. YEATS4 expression is also positively correlated with ZEB1 expression in patients with breast cancer. Co-expression of YEATS4 and ZEB1 correlates with the shortest distant metastasis-free period. Taken together, our data reveal the critical role of YEATS4 in the progression and metastasis of breast cancer, as well as support YEATS4 as a potential therapeutic target and prognostic biomarker for breast cancer.
含YEATS结构域蛋白4(YEATS4)与多种致癌信号通路相关,其表达涉及多种类型的癌症;尽管如此,YEATS4对乳腺癌的病理生理作用仍不清楚。本研究发现,YEATS4的表达随着乳腺癌进展而增加,其表达与不良预后和远处转移相关。乳腺癌细胞中YEATS4的过表达增强了它们的恶性特征,特别是诱导上皮-间质转化(EMT),从而增强了乳腺癌细胞的转移能力。相比之下,在高恶性程度的乳腺癌细胞中删除YEATS4可降低这些特征。关于分子机制,YEATS4在ZEB1启动子的特定位点介导组蛋白H3K27ac,以在转录水平调节其表达。敲低ZEB1可阻断YEATS4诱导的EMT、迁移、侵袭和转移。YEATS4的表达在乳腺癌患者中也与ZEB1的表达呈正相关。YEATS4和ZEB1的共表达与最短的无远处转移生存期相关。综上所述,我们的数据揭示了YEATS4在乳腺癌进展和转移中的关键作用,并支持YEATS4作为乳腺癌的潜在治疗靶点和预后生物标志物。